Nutritional impact of active hexose-correlated compound for patients with resectable or borderline-resectable pancreatic cancer treated with neoadjuvant therapy

AbstractActive hexose-correlated compound (AHCC) is a standardized extract from culturedLentinula edodes mycelia, used as a potent biological response modifier in cancer treatment. We evaluated the nutritional effect of AHCC, given during neoadjuvant therapy, to patients with pancreatic ductal adenocarcinoma (PDAC). Thirty patients with resectable or borderline-resectable PDAC received neoadjuvant therapy with gemcitabine plus S-1. We compared, retrospectively, the outcomes of 15 patients who received AHCC combined with neoadjuvant therapy with those of 15 patients who did not receive AHCC combined with neoadjuvant therapy. The median changes of the neutrophil-to-lymphocyte ratio (NLR) and prognostic nutrition index (PNI) were significantly better in the AHCC group. The relative dose intensity of neoadjuvant therapy was also significantly higher in the AHCC group. Thus, AHCC may improve the nutritional status during neoadjuvant therapy of patients with pancreatic ductal adenocarcinoma. To validate these results and examine the long-term impact of AHCC, a prospective phase II study for PDAC is ongoing.
Source: Surgery Today - Category: Surgery Source Type: research

Related Links:

Condition:   Pancreatic Ductal Adenocarcinoma Interventions:   Drug: Pembrolizumab;   Drug: Folfirinox Sponsors:   Baylor College of Medicine;   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions: CR-POPF after resection for PDAC is significantly associated with worse overall and disease-free survival.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Systematic Review Source Type: research
h Cornelis F. M. Sier Targeted molecular imaging may overcome current challenges in the preoperative and intraoperative delineation of pancreatic ductal adenocarcinoma (PDAC). Tumor-associated glycans Lea/c/x, sdi-Lea, sLea, sLex, sTn as well as mucin-1 (MUC1) and mucin-5AC (MU5AC) have gained significant interest as targets for PDAC imaging. To evaluate their PDAC molecular imaging potential, biomarker expression was determined using immunohistochemistry on PDAC, (surrounding) chronic pancreatitis (CP), healthy pancreatic, duodenum, positive (LN+) and negative lymph node (LN−) tissues, and quantified using a s...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
ooreman Advances in the treatment of pancreatic ductal adenocarcinoma (PDAC) using neoadjuvant chemoradiotherapy, chemotherapy, and immunotherapy have had minimal impact on the overall survival of patients. A general lack of immunogenic features and a complex tumor microenvironment (TME) are likely culprits for therapy refractoriness in PDAC. Induced pluripotent stem cells (iPSCs) should be explored as a means to advance the treatment options for PDAC, by providing representative in vitro models of pancreatic cancer development. In addition, iPSCs could be used for tailor-made cellular immunotherapies or as a source of...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Pathological treatment effect of resected pancreatic adenocarcinoma after neoadjuvant therapy has prognostic implications. The impact for patients who received chemotherapy alone or chemoradiotherapy is not well defined.
Source: Surgery - Category: Surgery Authors: Source Type: research
Ann Surg Oncol. 2021 Nov 1. doi: 10.1245/s10434-021-10991-2. Online ahead of print.ABSTRACTBACKGROUND: Neoadjuvant chemotherapy (NAC) is an integral part of preoperative treatment for patients with borderline resectable/locally advanced (BR/LA) pancreatic ductal adenocarcinoma (PDAC). The identification of a chemotherapeutic regimen that is both effective and tolerable is critical for NAC to be of oncologic benefit. After initial first-line (FL) NAC, some patients have lack of response or therapeutic toxicities precluding further treatment with the same regimen; optimal decision making regarding this patient population is ...
Source: Ann Oncol - Category: Cancer & Oncology Authors: Source Type: research
Conclusion: In a moderate fraction of GEP-NET patients, with or without liver metastases, whose primary tumor was unresectable because of vascular involvement, the primary tumor converted from unresectable to resectable after 177Lu-DOTATATE therapy, signifying that neoadjuvant PRRT can be considered in such patients. The effective control of symptoms, favorable morphologic and functional imaging response, and durable PFS and OS that we observed after 177Lu-DOTATATE PRRT may lead to less morbidity and mortality in these patients.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Featured Article of the Month Source Type: research
This study aimed to evaluate the clinical relevance of splenic vessel invasion with pancreatic body or tail cancer compared with no invasion and investigate prognostic factors.METHODS: This study enrolled patients who underwent upfront distal pancreatectomy from 2005 to 2018. The circular degree of splenic vessel invasion was investigated and categorized into three groups (group 1, no invasion; group 2, 0-180°; group 3, 180° or more). Clinicopathological variables and perioperative and survival outcomes were evaluated, and multivariable Cox proportional analysis was performed to evaluate prognostic factors.RESULTS:...
Source: The British Journal of Surgery - Category: Surgery Authors: Source Type: research
Neoadjuvant chemotherapy (NAC) is being utilized more frequently in patients with pancreatic adenocarcinoma (PDAC). Not all patients can tolerate modern multiagent regimens due to toxicity profiles or pre-existing comorbidities. We utilized institutional data and the National Cancer Database (NCDB) to investigate if the time from diagnosis to NAC start is associated with survival from surgery for PDAC.
Source: Journal of the American College of Surgeons - Category: Surgery Authors: Tags: Hepatobiliary and Pancreas Source Type: research
Conclusion: Preoperative CA19-9 ( ≥100 U/mL) was the most reliable preoperative predictive factor for poor survival in resectable PDAC treated with upfront surgery. These findings warrant further clinical trials investigating efficacy of neoadjuvant therapy targeting the subset of patients with resectable PDAC who have elevated pr eoperative CA19-9, namely, those with high risk of poor prognosis.Dig Surg
Source: Digestive Surgery - Category: Surgery Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Neoadjuvant Therapy | Nutrition | Pancreas | Pancreatic Cancer | Study | Surgery